{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"CML Acquisition of a new cytogenetic abnormality and/or development of accelerated phase or blast crisis. Criteria for accelerated phase: unexplained fever \\>38.3° C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, BM blasts and promyelocytes \\>20%.\n\nAML, ALL, CMML \\>30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.\n\nCLL Progressive disease: ≥1 of: physical exam/imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.\n\nNHL \\>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.\n\nMM\n\n≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ tx; or definite increase in the size/number of plasmacytomas or lytic bone lesions.","groups":[{"description":"Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI (1x10\\^7 CD3+ cells/kg) over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG000","title":"Group 1A (Pentostatin, DLI Dose Level 1)"},{"description":"Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI (3x10\\^7 CD3+ cells/kg) over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG001","title":"Group 1B (Pentostatin, DLI Dose Level 2)"},{"description":"Patients receive treatment as in group 1A. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG002","title":"Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)"},{"description":"Patients receive treatment as in group 1B. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG003","title":"Group 2D (Pentostatin, DLI Dose Level 2, Add'l IS)"}],"paramType":"NUMBER","populationDescription":"No subjects were enrolled onto Group 2D because the dose escalation was not triggered before the study closed to accrual.","reportingStatus":"POSTED","timeFrame":"1 year after DLI","title":"Incidence of Relapse/Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}